Synthroid Holding 75% Of Its Pre-Generic Script Share, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Script share for the levothyroxine brand is "within our range of expectations" since AB-rated generics entered the market, CFO Freyman says. Abbott predicted generic erosion for Synthroid would be less than that for other drugs due, in part, to the product's narrow therapeutic range.
You may also be interested in...
Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns
Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.
Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns
Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.
Biaxin Could Benefit From Flu Vaccine Shortage Ahead Of Generic Competition
Abbott cautions that it is too early in the flu season to accurately predict the potential sales impact on the antibiotic brand, which is expected to face generic competition in May 2005. The company’s fourth quarter forecast assumes a conservative impact from the flu vaccine shortage.